← Mechanisms of action
CD22
SINGLE PROTEINHomo sapiens
Linked proteins
Drugs acting on this target (59)
| Active Pharmaceutical Ingredient | Mechanism Type ▲ | Approval Status | API Type | Mechanism of Action |
|---|---|---|---|---|
| moxetumomab pasudotox (Lumoxiti) | Antagonist | approved | mAb | CD22 antagonist |
| bl22 | Binding agent | experimental | mAb | CD22 binding agent |
| Fab'-RFB4-dgA | Binding agent | experimental | mAb | CD22 |
| humanised anti-cd22 antibody | Binding agent | experimental | mAb | CD22 binding agent |
| inotuzumab ozogamicin (besponsa) | Binding agent | approved | mAb | CD22 binding agent |
| mono-dga-rfb4 | Binding agent | experimental | mAb | CD22 binding agent |
| moxetumomab pasudotox (Lumoxiti) | Binding agent | approved | mAb | CD22 binding agent |
| polatuzumab vedotin (Polivy) | Binding agent | approved | mAb | CD22 binding agent |
| 4scar22 | Immunity, passive | experimental | Cell therapy | CD22 immunity, passive |
| allogeneic donor-derived t-cells transduced with bivalent lentiviral vector (cd19/cd22-bbz) chimeric antigen receptor (car) | Immunity, passive | experimental | Cell therapy | CD22 immunity, passive |
| anti-cd19/cd20/cd22 car t-cells | Immunity, passive | experimental | Cell therapy | CD22 immunity, passive |
| autologous apd-l1 armored anti-cd22 car t cells | Immunity, passive | experimental | Cell therapy | CD22 immunity, passive |
| autologous cd19/cd22 car t cells | Immunity, passive | experimental | Cell therapy | CD22 immunity, passive |
| autologous cd19/cd22 chimeric antigen receptor t-cells | Immunity, passive | experimental | Cell therapy | CD22 immunity, passive |
| b019 | Immunity, passive | experimental | Cell therapy | CD22 immunity, passive |
| bi-4scar cd19/22 t cells | Immunity, passive | experimental | Cell therapy | CD22 immunity, passive |
| bze2204 | Immunity, passive | experimental | Cell therapy | CD22 immunity, passive |
| car-t targeted cd19/cd20/cd22/cd30 | Immunity, passive | experimental | Cell therapy | CD22 immunity, passive |
| car20.19.22 cells | Immunity, passive | experimental | Cell therapy | CD22 immunity, passive |
| car2219-t cells | Immunity, passive | experimental | Cell therapy | CD22 immunity, passive |
| cart22 | Immunity, passive | experimental | Cell therapy | CD22 immunity, passive |
| cd19/cd22-dual-star-t | Immunity, passive | experimental | Cell therapy | CD22 immunity, passive |
| cd20/cd22 targeted car t-cells | Immunity, passive | experimental | Cell therapy | CD22 immunity, passive |
| cd22 car-t cells | Immunity, passive | experimental | Cell therapy | CD22 immunity, passive |
| clic-2201 | Immunity, passive | experimental | Cell therapy | CD22 immunity, passive |
| crg-022 | Immunity, passive | experimental | Cell therapy | CD22 immunity, passive |
| gc022 | Immunity, passive | experimental | Cell therapy | CD22 immunity, passive |
| hy004 | Immunity, passive | experimental | Cell therapy | CD22 immunity, passive |
| lcar-aio cells | Immunity, passive | experimental | Cell therapy | CD22 immunity, passive |
| sc262 | Immunity, passive | experimental | Cell therapy | CD22 immunity, passive |
| scri-car22v2 | Immunity, passive | experimental | Cell therapy | CD22 immunity, passive |
| thiscart22 cells | Immunity, passive | experimental | Cell therapy | CD22 immunity, passive |
| ub-vv410 | Immunity, passive | experimental | Cell therapy | CD22 immunity, passive |
| ucart20x22 | Immunity, passive | experimental | Cell therapy | CD22 immunity, passive |
| universal dual specificity cd19 and cd20 or cd22 car-t cells | Immunity, passive | experimental | Cell therapy | CD22 immunity, passive |
| 90y-dota-epratuzumab | Inhibitor | experimental | mAb | CD22 inhibitor |
| adct-602 | Inhibitor | experimental | mAb | CD22 inhibitor |
| azd4512 | Inhibitor | experimental | mAb | CD22 inhibitor |
| bay1862864 | Inhibitor | experimental | mAb | CD22 inhibitor |
| bectumomab | Inhibitor | experimental | mAb | CD22 inhibitor |
| bl22 | Inhibitor | experimental | mAb | CD22 inhibitor |
| deglycosylated ricin a chain-conjugated anti-cd19/anti-cd22 immunotoxins | Inhibitor | experimental | mAb | CD22 inhibitor |
| dt2219arl | Inhibitor | experimental | mAb | CD22 inhibitor |
| humanised anti-cd22 antibody | Inhibitor | experimental | mAb | CD22 inhibitor |
| igg-rfb4-smpt-dga | Inhibitor | experimental | mAb | CD22 inhibitor |
| in111 ll2 igg | Inhibitor | experimental | mAb | CD22 inhibitor |
| inotuzumab ozogamicin (besponsa) | Inhibitor | approved | mAb | CD22 inhibitor |
| jnj-75348780 | Inhibitor | experimental | mAb | CD22 inhibitor |
| mono-dga-rfb4 | Inhibitor | experimental | mAb | CD22 inhibitor |
| monoclonal antibody mono-dga-rfb4 | Inhibitor | experimental | mAb | CD22 inhibitor |
| moxetumomab pasudotox (Lumoxiti) | Inhibitor | approved | mAb | CD22 inhibitor |
| polatuzumab vedotin (Polivy) | Inhibitor | approved | mAb | CD22 inhibitor |
| regn5837 | Inhibitor | experimental | mAb | CD22 inhibitor |
| sm03 | Inhibitor | experimental | mAb | CD22 inhibitor |
| sn1011 | Inhibitor | experimental | mAb | CD22 inhibitor |
| trph-222 | Inhibitor | experimental | mAb | CD22 inhibitor |
| bectumomab | Other | experimental | mAb | CD22 other |
| moxetumomab pasudotox (Lumoxiti) | Other | approved | mAb | CD22 other |
| 90y-epratuzumab tetraxetan | Radiodepletion | experimental | mAb | CD22 radiodepletion |